

We plan to conduct a pooled analysis combining YODA project data with data from the following additional studies. Please find below supplementary information we previously omitted:

- Additional studies:  
NCT02474355, NCT01085136, NCT00805194, NCT01953913, NCT00078260, NCT00789373, NCT00411229, NCT00275210, NCT01254279
- Data Source: Obtained from the Vivli Data Sharing Platform.
- Analysis Location: All individual patient data (IPD) analysis will be conducted at Chongqing Medical University via this platform. We maintain a secure data analysis environment and robust confidentiality measures.

Vivli Data Request	Requested Studies	Data Contributor	Study ID	Sponsor
D5160C00022	Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFR TKI).	AstraZeneca	NCT02474355	AstraZeneca

1200.42	<p>Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)</p>	Boehringer Ingelheim	NCT01085136	Boehringer Ingelheim
1199.13	<p>Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy</p>	Boehringer Ingelheim	NCT00805194	Boehringer Ingelheim

1200.66	An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)	Boehringer Ingelheim	NCT01953913	Boehringer Ingelheim
8433	A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy	Eli Lilly and Company	NCT00078260	Eli Lilly and Company
12560	A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung	Eli Lilly and Company	NCT00789373	Eli Lilly and Company

	Cancer.			
L_9570	A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxalip latin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma (CLASSIC)	Sanofi	NCT00411229	Sanofi
CR100857	A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer	Janssen Pharmaceutica N.V., Belgium	NCT02236637	Janssen Pharmaceutica N.V., Belgium

CR100900	<p>A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)</p>	Janssen Research & Development, LLC	NCT01715285	Janssen Research & Development, LLC
CABAZ_C_05331	<p>Multicentre, Single-arm, Open Label Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen and to Document Safety of Cabazitaxel in These Patients</p>	Sanofi	NCT01254279	Sanofi
EFC3313	<p>Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer</p>	Sanofi	NCT00275210	Sanofi

